ImmusanT

Biotechnology company developing diagnostics and therapeutics for the diagnosis and treatment of celiac disease.

Launch date

Jun 2011

Employees

Market cap

Enterprise valuation

Cambridge Massachusetts (HQ)

Date	Investors	Amount	Round
Dec 2011	Vatera Healthcare Partners	$20.0m	Series A
Dec 2014	Vatera Healthcare Partners	$12.8m	Series B
Nov 2017	Vatera Healthcare Partners ARCH Venture Partners	$40.0m	Series C
Sep 2018	JDRF T1D Fund	N/A	Early VC
Total Funding		AUD113m

Tech stackLearn more about the technologies and tools that this company uses.

Recent News about ImmusanT